ReviewNutrients2018
Chinese Medicines in the Treatment of Prostate Cancer: From Formulas to Extracts and Compounds.
Review in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies.International journal of molecular sciences · 2020Pooled it
- Article
- Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Trillin inhibits MAP3K11/NF-κB/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer.iScience · 2025Article
- Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Frontiers in cell and developmental biology · 2025Review
- Network pharmacology combined with molecular docking revealed the potential targets of Coridius chinensis in prostate cancer treatment.World journal of clinical cases · 2024Article
- Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology.BMC complementary medicine and therapies · 2024Article
- Network pharmacology and experimental validation to explore the role and potential mechanism of Liuwei Dihuang Decoction in prostate cancer.BMC complementary medicine and therapies · 2024Article
- Hederagenin Induces Apoptosis of Human Hepatoma HepG2 CellsCombinatorial chemistry & high throughput screening · 2024Article
- Mechanisms of action ofFrontiers in pharmacology · 2024Article
- Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice.Chinese herbal medicines · 2023Review
- Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer.Nutrients · 2023Article
- An Integrated Strategy for Investigating Antioxidants fromAntioxidants (Basel, Switzerland) · 2023Article
- Article
- A Mechanism of Isoorientin-Induced Apoptosis and Migration Inhibition in Gastric Cancer AGS Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Phytochemical characterization, antioxidant potential, and health risk assessment of Radix Oryzae Glutinosae.Journal of food and drug analysis · 2022Article
- Chaihu-Shugan-San ameliorates tumor growth in prostate cancer promoted by depressionFrontiers in pharmacology · 2022Article
- BK002 Induces miR-192-5p-Mediated Apoptosis in Castration-Resistant Prostate Cancer CellsFrontiers in oncology · 2022Article
- Improvement of cytotoxicity and necrosis activity of ganoderic acid a through the development of PMBN-A.Her2-GA as a targeted nano system.RSC advances · 2021Article
- Effects of Psychological Intervention on Perioperative Quality of Life and Serum PSA and FPSA Levels of Patients with Prostate Cancer Treated with Integrated Traditional Chinese and Western Medicine.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to fully understand the progresses and achievements in Chinese medicines for the treatment of prostate cancer, we summarize all the available reports on formulas, extracts, and compounds of Chinese medicines against prostate cancer. A number of clinical trials verified that traditional Chinese formulas had some unique advantages in the treatment of prostate cancer. Many Chinese medicine extracts could protect against prostate cancer, and many compounds isolated from Chinese traditional medicines showed a clear anti-prostate cancer effect. However, Chinese medicines are facing many problems regarding their multicomponent nature, complicated mechanisms of action, and high doses required for therapy. Herein, we review the functions of Chinese medicines in prostate cancer and focus on their mechanisms. The review will deepen the understanding of Chinese medicines potential in the anti-prostate cancer field. In addition, we put forward a question concerning the current research on Chinese medicines: in order to better illustrate that Chinese medicines can be used in the clinical treatment of prostate cancer, should our research focus on formulas, extracts, or compounds?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.